Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Research & Development: 2012-2024

Historic Research & Development for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $127.6 million.

  • Ocular Therapeutix's Research & Development rose 41.30% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.3 million, marking a year-over-year increase of 82.11%. This contributed to the annual value of $127.6 million for FY2024, which is 109.05% up from last year.
  • As of FY2024, Ocular Therapeutix's Research & Development stood at $127.6 million, which was up 109.05% from $61.1 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Research & Development peaked at $127.6 million during FY2024, and registered a low of $28.7 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $61.1 million (2023), whereas its average is $80.7 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Research & Development slumped by 30.17% in 2020, and later spiked by 109.05% in 2024.
  • Ocular Therapeutix's Research & Development (Yearly) stood at $28.7 million in 2020, then soared by 74.54% to $50.1 million in 2021, then grew by 6.75% to $53.5 million in 2022, then climbed by 14.20% to $61.1 million in 2023, then spiked by 109.05% to $127.6 million in 2024.